This Market Spotlight report covers the Ischemic Stroke market, comprising key marketed and pipeline drugs, clinical trials, recent events and analyst opinion, upcoming and regulatory events, probability of success, and a 10-year disease prevalence forecast, as well as licensing and acquisition deals.
Key Takeaways
Key Takeaways
- The publisher estimates that in 2018, there were approximately 82.3 million prevalent cases of ischemic stroke worldwide, and forecasts that number to increase to 88.0 million prevalent cases by 2027.
- The approved drugs in the ischemic stroke space focus on a wide variety of targets. Most approved drugs are administered orally, with two drugs administered intravenously and one drug administered subcutaneously.
- The majority of industry-sponsored drugs in active clinical development for ischemic stroke are in Phase II. Therapies in active clinical development for ischemic stroke focus on a wide variety of targets and include small molecules, peptides, and cell-based therapies.
- High-impact upcoming events for drugs in the ischemic stroke space comprise topline Phase II trial results for Trans Sodium Crocetinate, TMS-007, and S-005151, topline Phase IIb trial results for ReN001, topline Phase III trial results for Cirara, and an expected supplemental CHMP opinion for Brilinta.
- The overall likelihood of approval of a Phase I ischemic stroke asset is 0.8%, and the average probability a drug advances from Phase III is 11.1%. Drugs, on average, take 13.3 years from Phase I to approval, compared to 9.8 years in the overall neurology space.
- The distribution of clinical trials across Phase I–IV indicates that the majority of trials for stroke have been in the early and midphases of development, with 70% of trials in Phase I–II, and 30% in Phase III–IV.
- The US has a substantial lead in the number of stroke clinical trials globally. Germany leads the major European markets, while China has the top spot in Asia.
- Clinical trial activity in the stroke space is dominated by completed trials. Roche has the highest number of completed clinical trials for stroke, with 21 trials.
- Roche leads industry sponsors with the highest overall number of clinical trials for stroke, followed by Boehringer Ingelheim and Daiichi Sankyo
Table of Contents
OVERVIEWKEY TAKEAWAYSEPIDEMIOLOGYMARKETED DRUGSPIPELINE DRUGSKEY UPCOMING EVENTSPROBABILITY OF SUCCESSREVENUE OPPORTUNITYBIBLIOGRAPHYAPPENDIX
DISEASE BACKGROUND
TREATMENT
RECENT EVENTS AND ANALYST OPINION
KEY REGULATORY EVENTS
CLINICAL TRIAL LANDSCAPE
LIST OF FIGURES
LIST OF TABLES
